Interventional Spine has announced US Food and Drug Administration (FDA) clearance of its Lateral Opticage expandable intervertebral body fusion device. This device joins the Interventional Spine family of Opticage expandable interbody fusion devices previously cleared for TLIF earlier this year, and used with the company’s PerX360 system.
The Opticage device is a lumbar intervertebral body fusion device and is indicated for use with autogenous bone graft in patients with degenerative disc disease at one or two contiguous levels from L2-S1. The Opticage device can be implanted via posterior, transforaminal or lateral approach.
Walter A Cuevas, chief executive officer of Interventional Spine says: “With this milestone, Interventional Spine continues to lead the spine market in providing the most innovative solutions for surgeons, which in the end, benefit patients.”
